Walleye Capital LLC Lowers Holdings in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)

Walleye Capital LLC reduced its stake in shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERIGet Rating) by 28.5% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 269,110 shares of the company’s stock after selling 107,213 shares during the period. Walleye Capital LLC owned approximately 0.55% of Aerie Pharmaceuticals worth $2,449,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Nordea Investment Management AB raised its stake in shares of Aerie Pharmaceuticals by 14.2% during the 1st quarter. Nordea Investment Management AB now owns 38,309 shares of the company’s stock worth $356,000 after buying an additional 4,751 shares during the last quarter. Virginia Retirement Systems ET AL acquired a new position in Aerie Pharmaceuticals in the 1st quarter valued at about $105,000. Hazlett Burt & Watson Inc. acquired a new position in Aerie Pharmaceuticals in the 1st quarter valued at about $207,000. Granite Investment Partners LLC grew its holdings in Aerie Pharmaceuticals by 12.7% in the 1st quarter. Granite Investment Partners LLC now owns 538,152 shares of the company’s stock valued at $4,897,000 after buying an additional 60,702 shares during the period. Finally, IndexIQ Advisors LLC purchased a new stake in Aerie Pharmaceuticals in the 1st quarter valued at about $383,000. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Stifel Nicolaus cut Aerie Pharmaceuticals from a “buy” rating to a “hold” rating and set a $15.00 price target for the company. in a report on Tuesday, August 23rd. Truist Financial cut Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 24th. Cantor Fitzgerald cut Aerie Pharmaceuticals from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $30.00 to $15.25 in a report on Tuesday, August 23rd. HC Wainwright cut Aerie Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, August 24th. Finally, StockNews.com upgraded Aerie Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday. Six equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $16.90.

Aerie Pharmaceuticals Stock Down 0.5 %

NASDAQ AERI opened at $15.14 on Friday. The business has a 50 day moving average price of $11.18 and a two-hundred day moving average price of $8.81. Aerie Pharmaceuticals, Inc. has a fifty-two week low of $4.81 and a fifty-two week high of $15.37. The stock has a market cap of $747.31 million, a PE ratio of -14.22 and a beta of -0.06.

Aerie Pharmaceuticals (NASDAQ:AERIGet Rating) last announced its earnings results on Thursday, August 4th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.20. The business had revenue of $33.31 million during the quarter, compared to analyst estimates of $32.47 million. During the same period in the previous year, the company earned ($0.67) earnings per share. Sell-side analysts anticipate that Aerie Pharmaceuticals, Inc. will post -1.97 EPS for the current fiscal year.

Aerie Pharmaceuticals Company Profile

(Get Rating)

Aerie Pharmaceuticals, Inc, a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension.

Further Reading

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.